Novartis stock was flat Tuesday after the pharma giant lagged first-quarter expectations, but retained its outlook for 2026 sales and profit. The post Novartis Yo-Yoes As Generics Take A Bite Out Of Its First-Quarter Sales appeared first on Investor&#039;s Business Daily.

Novartis stock was flat Tuesday after the pharma giant lagged first-quarter expectations, but retained its outlook for 2026 sales and profit. The post Novartis Yo-Yoes As Generics Take A Bite Out Of Its First-Quarter Sales appeared first on Investor's Business Daily.

Novartis Yo-Yoes As Generics Take A Bite Out Of Its First-Quarter Sales

Source Information